GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoTherapy Science Inc (TSE:4564) » Definitions » Capex-to-Revenue

OncoTherapy Science (TSE:4564) Capex-to-Revenue : 0.00 (As of Sep. 2024)


View and export this data going back to 2003. Start your Free Trial

What is OncoTherapy Science Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

OncoTherapy Science's Capital Expenditure for the three months ended in Sep. 2024 was 円0.00 Mil. Its Revenue for the three months ended in Sep. 2024 was 円0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


OncoTherapy Science Capex-to-Revenue Historical Data

The historical data trend for OncoTherapy Science's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoTherapy Science Capex-to-Revenue Chart

OncoTherapy Science Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.42 0.13 0.40 0.01 -

OncoTherapy Science Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OncoTherapy Science's Capex-to-Revenue

For the Biotechnology subindustry, OncoTherapy Science's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoTherapy Science's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoTherapy Science's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where OncoTherapy Science's Capex-to-Revenue falls into.



OncoTherapy Science Capex-to-Revenue Calculation

OncoTherapy Science's Capex-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-2.627) / 610.118
=0.00

OncoTherapy Science's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoTherapy Science  (TSE:4564) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


OncoTherapy Science Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of OncoTherapy Science's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoTherapy Science Business Description

Traded in Other Exchanges
N/A
Address
11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.

OncoTherapy Science Headlines

No Headlines